Drug intelligence / Profile preview

BLS-A01

Development stage: Preclinical
Lead developer: MOA Life Plus
Modality: Vaccines & Immunotherapeutics

Overview

BLS-A01 is a prophylactic vaccine developed by MOA Life Plus Co., Ltd. It is primarily indicated for COVID-19 and is currently in the preclinical phase. The drug targets infectious diseases, including respiratory diseases.

Beyond the preview

Go deeper on BLS-A01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLS-A01.

Explore the full profile